Though a Phase III trial of Biocon Ltd.'s anti-CD6 mAb itolizumab did not show as much efficacy as other biologics in psoriasis, the biotech thinks lower infection rates could differentiate the mAb from the anti-TNFs.

Biocon this month announced itolizumab met the primary endpoint of PASI 75 improvement compared to placebo after 12 weeks (36% vs. 2%, p<0.0043) in the Indian Phase III TREAT-PLAQ trial in 223 patients with moderate to severe psoriasis.